$1 bn US settlement talk spooks Ranbaxy stock
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories' stock continues to face the heat on Indian bourses, hit by reports that it may have to find more than $1 billion to settle long-running unresolved manufacturing deficiencies at some of its plants and allegations of falsifying data with the US FDA.